SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Hank who wrote (6005)12/28/1998 1:30:00 PM
From: Linda Kaplan  Read Replies (1) of 7041
 
BEAR STEARNS December 22, 1998
THE BOTTLE REPORT
A Weekly Pharmaceutical Newsletter on Trade, Company, and Industry News

Extra Testing Requirements May Extend Impotence Drug Development Timelines.

The FDA is apparently requiring developers of impotence drugs to conduct drug-drug interaction studies in
order to determine their safety when used along with certain heart medications. These additional studies are
likely to stretch out the clinical timeframe by 3-6 months for companies developing oral products for erectile
dysfunction (table). This latest requirement is a minor positive for Viagra as it could delay competitive
launches by a few months.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext